© The Financial Times Ltd 2014 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Oct 17, 2014, the consensus forecast amongst 7 polled investment analysts covering CTI BioPharma Corp advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 04, 2013. The previous consensus forecast advised investors to purchase equity in CTI BioPharma Corp.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 6 analysts offering 12 month price targets for
Dividend information is not available for
On Aug 04, 2014,
|Average growth rate||-6.32%|
|Average growth rate||+45.22%|
CTI BioPharma Corp. had 2nd quarter 2014 revenues of 1.34m. This missed the 15.73m consensus estimate of the 3 analysts following the company. This was 4.82% below the prior year's 2nd quarter results. View Full Interim Financials
|Average growth rate||+57.12%|
CTI BioPharma Corp. had revenues for the full year 2013 of 2.31m. View Full Annual Financials
|Average growth rate||+66.25%|